Preclinical studies have claimed TGF-β signalling molecules as promising anti-fibrotic drug targets in various organ fibrosis animal models, whereas a vast majority of clinical studies have not yet achieved an acceptable level of therapeutic performance. Here, TGFB1 is linked to fibrosis.